Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

The State of Comparative Effectiveness Research and the Environment for Decision-Making (2011)

Comparative effectiveness research (CER) has gained in national prominence in recent years through an infusion of federal funds and passage of the Patient Protection and Affordable Care Act (PPACA), which established the non-profit Patient-Centered Outcomes Research Institute (PCORI) to oversee this important research.  Although PPACA is still facing challenges in the courts and Congress, many provisions of the law, including the establishment of PCORI, are already being implemented. While this foundational work is underway, the National Pharmaceutical Council, working with the public health research firm Social & Scientific Systems (SSS), examined the environment for health care decisions, especially the current state of CER and its impact on medical decision-making.

The purpose was to set a baseline for where key stakeholders believe we are today on CER and for tracking progress and judging future effects. According to the findings, there is clear recognition among key health care influentials about the importance of CER and its promise for the future. These stakeholders also expressed tempered optimism about progress in efforts to provide or improve the tools necessary for this research, and that any significant effects of CER are yet to be realized, and much work remains to be done.

CER Survey Highlights:

CER has “arrived” as a key issue in the health care conversation.

  • Nearly 6 in 10 of survey respondents were “very familiar” with comparative effectiveness research and about 30 percent of respondents were “somewhat familiar” with CER
  • CER was cited as “very important” to three-quarters of respondents or their organizations
  • Roughly one-third were “very familiar” with the Patient-Centered Outcomes Research Institute

Stakeholders feel we are moving gradually, but in the right direction, in establishing CER.

  • Respondents acknowledge that there is a greater availability of research methods and standards, as well as improvements in research priorities addressing treatment choices faced by patients and providers.
  • Respondents felt there was increasing movement from solely considering clinical effectiveness to evaluating a fuller picture of quality of life, workplace productivity effects, quality of care and the potential for improved adherence to treatments.

Stakeholders feel that over time CER will likely improve health care; however changes have not substantially taken root yet and the full impact may require significantly more time.

  • Only 30 percent believed that CER would lead to moderate improvements in health care decision-making in the next year.

Stakeholders recognize the key players on CER

  • Overwhelmingly, surveyed stakeholders believe that AHRQ will continue to play a significant role in CER during the next five years, particularly in the development of research standards (78 percent) and priorities (74 percent), with NIH (64 percent; 69 percent) and PCORI (50 percent; 63 percent) also taking an active role.
  • PCORI’s slightly lower positioning on establishing research standards may reflect the newness of the organization and its need to communicate goals and mission to audiences.

Respondents have clear expectations on the entities that will fund and conduct CER

  • Survey respondents said that the role of funding CER fell most significantly to NIH (81 percent), AHRQ (74 percent), and the pharmaceutical and medical products industry (68 percent).
  • In terms of conducting CER, respondents overwhelmingly pointed to academia (85 percent) as the main driver, followed by the pharmaceutical/medical products industry (62 percent).

CER Survey Parameters:

The survey, conducted from November 2010-March 2011, targeted key stakeholders who have an impact on, or are affected by, research involving medical effectiveness, including government, researchers, insurers, employers, human resource consultants and healthcare coalitions, and trade and other groups. A total of 118 stakeholders participated.

Survey materials:

Newsletter Volume

E.V.I.dently October 2014

Message From NPCMind the Gap: Improving Quality Measurement in Accountable Care SystemsOur society is obsessed with quality, from the cars that we...
Blog Post

CER Tweets of the Week: Fendrick Elected to IOM, GAO Calls to Fill PCORI Methodology Committee Seat & More (October 20-24)

This week, comparative effectiveness research (CER) stakeholders tweeted about new appointments and open positions at top health care organizations....
Blog Post

CER Tweets of the Week: The State of Accountable Care, JAMA on PCORI’s Perspective, Real-World Impact of CER (October 13-17)

Health care stakeholders tweeted about accountable care, patient-centered outcomes research (PCOR) and the real-world impact of comparative...
Blog Post

#TBT: National Boss’ Day—Celebrating Dan Leonard’s Six Years of Leadership

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Press Release

Fellowship in Health Care Policy Available Through a Partnership of the National Pharmaceutical Council and Milken Institute School of Public Health at The George Washington University

WASHINGTON, DC (September 17, 2014)–The National Pharmaceutical Council (NPC), in conjunction with Milken Institute School of Public Health (Milken...
Press Release

Michael Ciarametaro Joins National Pharmaceutical Council as Director of Research

WASHINGTON, DC (July 31, 2014)—The National Pharmaceutical Council (NPC) today announced that Michael Ciarametaro has joined the health policy...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon

(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use of comparative effectiveness research...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

CER and the Environment for Health Care Decision-Making

The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is continuing to shed light on the current environment...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
YouTube Videos

Engaging Patients in Research

National Pharmaceutical Council President Dan Leonard explains why it's important to include patients throughout the research process. He says that...
Blog Post

CER Tweets of the Week: Fendrick Elected to IOM, GAO Calls to Fill PCORI Methodology Committee Seat & More (October 20-24)

This week, comparative effectiveness research (CER) stakeholders tweeted about new appointments and open positions at top health care organizations....
Blog Post

CER Tweets of the Week: The State of Accountable Care, JAMA on PCORI’s Perspective, Real-World Impact of CER (October 13-17)

Health care stakeholders tweeted about accountable care, patient-centered outcomes research (PCOR) and the real-world impact of comparative...
Blog Post

#TBT: National Boss’ Day—Celebrating Dan Leonard’s Six Years of Leadership

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

A Day in the Life: Dr. Shih Talks About His NPC-Milken Institute SPH Fellowship

In 2012, the National Pharmaceutical Council (NPC) and the Milken Institute School of Public Health (Milken Institute SPH) at The George Washington...

Research

  •  
  • 1 of 13
  • >

Commentary & Testimony